Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials according to brca mutational status
It is by now widely recognized that ovarian cancer (OC) harbours a remarkable degree of genomic disarray and instability and presents with a wide range of mutations [1,2]. Indeed, around 50% of all high-grade serous ovarian tumours are estimated to have a deficiency in the homologous recombination (HR) DNA repair mechanism, with about 15% of carcinomas harbouring a germline and 6% a somatic Breast Related Cancer Antigens (BRCA) 1-2 mutation. These mutations confer to the cell a disability to repair DNA through the HR pathway, leading to a condition defined as homologous recombination deficiency (HRD) [1,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Federica Tomao, Erlisa Bardhi, Anna Di Pinto, Carolina Maria Sassu, Elena Biagioli, Maria Cristina Petrella, Innocenza Palaia, Ludovico Muzii, Nicoletta Colombo, Pierluigi Benedetti Panici Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Disability | Gastroschisis Repair | Ovarian Cancer | Ovaries | Serous Carcinoma | Study